Synaffix adds to the flurry of ADC dealmaking as it partners with Boehringer and Mitsubishi Tanabe with deals announced on the same day.

Newron and Myung In Pharm have signed a licence agreement for evenamide, for schizophrenia treatment in South Korea.

Financing was co-led by Forbion and General Atlantic, with participants including RA Capital Management, OrbiMed, and Lilly Asia Ventures.

The EC has approved the extension of Stallergenes Greer’s Palforzia for the treatment of peanut allergy in toddlers.

Under the deal, Candid will have exclusive global rights to a tri-specific TCE discovered by WuXi using its WuXiBody platform. The Chinese company is set to receive an undisclosed upfront payment, as ...

Aspect Biosystems has secured $115m in a Series B financing round to advance the development of bioprinted tissue therapeutics.

Novo Nordisk has expanded its partnership with Valo Health to advance new therapies for type 2 diabetes, obesity and cardiometabolic disease.

As part of the agreement, Sanofi will provide Alloy with upfront license fees and near-term preclinical milestone payments up to $27.5m.

With clinical trials facing multiple challenges, digital solutions could provide the answer. We identify the key trends to watch in 2025.

China's National Medical Products Administration has granted expanded approval to MSD's GARDASIL for use in males aged nine to 26 years.

Araris will use its linker technology to generate multi-warhead ADCs for “undisclosed targets” provided by Chugai.

Orna will receive a $65m upfront payment and is eligible to receive potential milestone payments and royalties.